Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both disease modification and symptom management. The biopharmaceutical company is developing Lucid-MS, an investigational therapy for multiple sclerosis (MS), and unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism. These initiatives reflect a broader commitment to tackling challenging neurodegenerative and metabolic disorders.
Lucid-MS is positioned as a potential breakthrough in MS treatment by targeting PAD2, an enzyme implicated in myelin degradation. Unlike conventional therapies that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, which is crucial for nerve function. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial, marking a significant step forward in clinical development. Additionally, Quantum BioPharma is supporting this effort through an imaging collaboration with Massachusetts General Hospital, which could provide valuable insights into the drug's effects on myelin integrity.
In parallel, Quantum BioPharma's unbuzzd supplement is designed to enhance alcohol metabolism, reducing acute intoxication and hangover symptoms. The company cites results from a randomized, placebo-controlled clinical trial supporting these benefits. This consumer-focused product complements the pharmaceutical pipeline and offers a more immediate avenue for addressing alcohol misuse disorders, a significant public health concern.
The company's strategy extends beyond development. Quantum BioPharma has spun out the over-the-counter version of unbuzzd to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement allows Quantum BioPharma to benefit from commercial success while retaining 100% of rights to develop pharmaceutical-grade formulations of similar products for medical use.
Lucid-MS is being developed through Quantum BioPharma's wholly owned subsidiary, Lucid Psycheceuticals Inc. The compound is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. This novel mechanism of action could differentiate it from existing treatments that focus on immune modulation, potentially offering a disease-modifying option that directly addresses the core pathology.
The recent IND submission for Lucid-MS and the ongoing clinical trial for unbuzzd underscore Quantum BioPharma's commitment to advancing its pipeline. The company's focus on neurological health, combined with strategic partnerships and a diversified approach, positions it to potentially address significant unmet medical needs. As these programs progress, they may offer new hope for patients suffering from MS and alcohol-related disorders.
For more information about Quantum BioPharma and its developments, visit the company's newsroom at https://ibn.fm/QNTM.
